Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + VRd versus VRd in transplant-ineligible newly diagnosed multiple myeloma
CTR20180937Phase 3Active
- Sponsor
- Sanofi
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of isatuximab in multiple myeloma (MM), sponsored by Sanofi. Started Nov 2018; status: active.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20180937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180937.